Cross-validation of optimized composites for preclinical Alzheimer's disease.

ABSTRACT:

Introduction

We discuss optimization and validation of composite endpoints for pre-symptomatic Alzheimer's clinical trials. Optimized composites offer hope of substantial gains in statistical power or reduction in sample size. But there is tradeoff between optimization and face validity such that optimization should only be considered if there is a convincing rationale. As with statistically derived regions of interest in neuroimaging, validation on independent datasets is essential.

Methods

Using four datasets, we consider the optimized weighting of four components of a cognitive composite which includes measures of (1) global cognition, (2) semantic memory, (3) episodic memory, and (4) executive function. Weights are optimized to either discriminate amyloid positivity or m

SUBMITTER: Donohue MC 

PROVIDER: S-EPMC5527287 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature